Purchasers of AstraZeneca LP’s heartburn medication Nexium were not entitled to a new trial to their challenge of “reverse payment” agreements between AstraZeneca and Ranbaxy Pharmaceuticals that allegedly blocked the entry of a generic version of the drug, the U.S. Court of Appeals in Boston has decided. The plaintiffs’ argument that the trial court improperly…